NCAM1 and metastatic colorectal cancer: found that CIK cells plus chemotherapy-treated patients with metastatic colorectal cancer with an increased number of CD3+CD56+ subgroups had a better OS rate than those with a reduced number of CD3+CD56+ subgroups (41).